Summary
DRRX Chart
Durect (DRRX) Reports Q2 Loss, Tops Revenue Estimates
Durect (DRRX) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.12 per share a year ago.
DURECT Corporation (DRRX) Q4 2024 Earnings Call Transcript
DURECT Corporation (NASDAQ:DRRX ) Q4 2024 Earnings Conference Call March 26, 2025 4:30 PM ET Company Participants Tim Papp - Chief Financial Officer Jim Brown - Co-Founder, Chief Executive Officer, President, Director Norman Sussman - Chief Medical Officer WeiQi Lin - Executive Vice President, Research & Development and Principal Scientist Conference Call Participants François Brisebois - Oppenheimer & Company Karl Burns - Northland Capital Markets Thomas Yip - H.C. Wainwright Operator Greetings and welcome to the DURECT Corporation Fourth Quarter and Full-Year 2024 Earnings Conference Call.
Durect (DRRX) Reports Q4 Loss, Lags Revenue Estimates
Durect (DRRX) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of $0.06. This compares to loss of $0.27 per share a year ago.
Durect Corporation Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Jeffrey Gundlach DoubleLine Capital LP | 25,000 | $320,000 | $32,000 | -$288,000 | -90% |
Durect Corporation (DRRX) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Durect Corporation Profile
| - Industry | - Sector | James E. Brown D.V.M. CEO | NASDAQ (CM) Exchange | 266605104 CUSIP |
| US Country | 21 Employees | - Last Dividend | 6 Dec 2022 Last Split | 28 Sep 2000 IPO Date |
Overview
DURECT Corporation is a biopharmaceutical entity focused on the innovation of drugs, harnessing the potential of its epigenetic regulator program to discover and develop novel therapeutic solutions. Its journey began in 1998, with its foundations laid in Cupertino, California. The company has embarked on a mission to create impactful medicines, particularly emphasizing conditions such as alcohol-associated hepatitis and nonalcoholic steatohepatitis, using its lead product, larsucosterol (DUR-928). DURECT's strategy extends beyond its pioneering drug development; it includes forging strategic collaborations and partnerships, notably with the Virginia Commonwealth University Intellectual Property Foundation, Indivior UK Ltd., and Innocoll Pharmaceuticals Limited, to broaden its reach and enhance its capacity to address various medical needs.
Products and Services
- Larsucosterol (DUR-928)
This flagship product of DURECT is a testament to its innovative approach in the biopharmaceutical space. Larsucosterol is an endogenous, orally bioavailable small molecule, currently in a Phase IIb clinical trial. Its function as an epigenetic regulator allows it to modulate lipid metabolism, stress responses, inflammatory responses, as well as cell death and survival processes. The primary aim is to treat alcohol-associated hepatitis and nonalcoholic steatohepatitis, having already completed a Phase Ib clinical trial for the latter.
- ALZET Product Line
The ALZET range includes osmotic pumps and accessories, designed for meticulous research applications within mice, rats, and other laboratory animals. These products underscore DURECT's commitment to supporting foundational research efforts that underpin future therapeutic breakthroughs. The company markets these products through a direct sales force in the United States, supplemented by a network of distributors internationally.
- POSIMIR
Recognizing the critical need for effective pain management post-surgery, DURECT developed POSIMIR. This product is geared towards delivering bupivacaine, a local anesthesia, over a three-day period to adults undergoing surgical procedures. It exemplifies DURECT's dedication to enhancing patient care and recovery outcomes.
- Methydur
Addressing the challenges of attention deficit hyperactivity disorder (ADHD), DURECT offers Methydur. This therapeutic solution is targeted at improving the lives of individuals dealing with ADHD, showcasing the company's broader interest in addressing multifaceted health concerns.
